Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS2 Score: A Subgroup Analysis of the RE-LY Trial

Study Questions:

What is the prognostic importance of the CHADS2 risk score in terms of stroke, bleeding, and death in patients with atrial fibrillation receiving the vitamin K antagonist warfarin and the direct thrombin inhibitor dabigatran?